Lung Cancer Survival Improved With New Combo Therapy
Patients with a specific genetic mutation saw survival benefits from a new first-line treatment regimen.
Updated on Sept. 30, 2026 in Cancer
The Phase 3 PAPILLON study found that combining the drug amivantamab with chemotherapy improved overall survival in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations. This marks a notable outcome for those facing this particular type of lung cancer.
Why it matters
This development offers a potential new standard for first-line care, providing a more effective way to manage advanced lung cancer characterized by this specific genetic driver. It changes how clinicians may approach initial treatment strategies to better extend survival for this patient group.
In the Phase 3 PAPILLON trial, researchers compared first-line amivantamab plus chemotherapy against chemotherapy alone in patients with advanced NSCLC and EGFR Exon 20 insertions. The combination showed a statistically significant overall survival benefit after adjusting for patient crossover.
The players
PAPILLON study
A Phase 3 clinical trial investigating treatment options for patients with advanced non-small cell lung cancer.
The details
Amivantamab functions by targeting both the EGFR and MET receptors, which are often involved in driving tumor growth. By combining this therapy with traditional chemotherapy, the treatment aims to disrupt these signaling pathways more effectively than chemotherapy on its own. Researchers performed a statistical adjustment to account for the impact of patients in the chemotherapy-only group who later switched to amivantamab as a second-line therapy.
Health Landscape
The PAPILLON study marks a significant evolution in the treatment landscape for patients with EGFR Exon 20 insertion mutations. It provides a new benchmark for overall survival compared to the long-standing standard of using chemotherapy alone as a first-line intervention.
If you or a loved one are managing advanced NSCLC, discuss whether EGFR Exon 20 insertion mutation testing has been completed. These findings are worth reviewing with an oncologist to understand how current treatment protocols for lung cancer continue to shift toward precision-based combinations.
The takeaway
The PAPILLON trial confirms that combining targeted therapy with chemotherapy can offer improved outcomes for specific lung cancer mutations. Patients should consult with their oncology team about the latest clinical evidence to determine if new combination therapies are appropriate for their care plan.
Further reading
For more information on the latest advancements in oncology, visit our Cancer section.
Source note: This article includes information reported by OncLive.
